Key result
KCNE2 overexpression ameliorates systolic and diastolic dysfunction in diabetic mice by improving Ca2+ cycling.
Why the study?
Diabetic cardiomyopathy is associated with impaired calcium handling and SERCA2a downregulation, but the underlying regulatory mechanisms remain poorly understood.
Does KCNE2 upregulation improve cardiac function in diabetic cardiomyopathy models?
Does KCNE2 upregulation improve cardiac function in diabetic cardiomyopathy models?
KCNE2 upregulation protects against diabetic cardiomyopathy by stabilizing SERCA2a through the inhibition of Smurf1-mediated degradation, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
KCNE2-SERCA2a regulation in diabetic models is hypothesis-generating; human studies needed before any clinical relevance.
Diabetic cardiomyopathy (DCM) is associated with impaired calcium handling and downregulation of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 2a (SERCA2a), though the underlying regulatory mechanisms remain poorly understood. Here, we identify KCNE2, an auxiliary β-regulatory subunit of multiple ion channels, as a key regulator of SERCA2a protein stability in the diabetic heart. KCNE2 expression was significantly reduced in high fat diet/streptozotocin-induced diabetic mice and palmitic acid-treated cardiomyocytes. Using LC-MS/MS and co-immunoprecipitation, SERCA2a was identified as a direct binding partner of KCNE2. Knockdown of KCNE2 decreased SERCA2a protein levels without affecting its transcription. Cardiac-specific overexpression of KCNE2 via adenovirus-associated virus 9 delivery restored SERCA2a expression, improved sarcoplasmic reticulum Ca²⁺ cycling, and ameliorated systolic and diastolic dysfunction in diabetic mice. Mechanistically, KCNE2 competitively inhibited the interaction between SERCA2a and the E3 ubiquitin ligase Smurf1, thereby suppressing Smurf1-mediated polyubiquitination and proteasomal degradation of SERCA2a. These results reveal a novel protective role of KCNE2 in diabetic hearts and propose KCNE2 upregulation as a potential therapeutic strategy for DCM. Upregulation of KCNE2 ameliorates cardiac dysfunction by reducing Smurf1-mediated SERCA2a polyubiquitination and degradation, and re-establishes SR Ca²⁺ homeostasis in DCM.
No takes yet. Share an insight, caveat, or question.
Ming et al. (2026) studied Diabetic cardiomyopathy. KCNE2 overexpression via AAV9 was evaluated on Cardiac function and SERCA2a protein stability. Cardiac-specific overexpression of KCNE2 improved sarcoplasmic reticulum Ca2+ cycling and ameliorated systolic and diastolic dysfunction in diabetic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: